Home Cart 0 Sign in  

[ CAS No. 1256784-52-7 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1256784-52-7
Chemical Structure| 1256784-52-7
Structure of 1256784-52-7 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 1256784-52-7 ]

Related Doc. of [ 1256784-52-7 ]

Alternatived Products of [ 1256784-52-7 ]

Product Details of [ 1256784-52-7 ]

CAS No. :1256784-52-7 MDL No. :MFCD14582651
Formula : C20H30BNO5 Boiling Point : -
Linear Structure Formula :- InChI Key :IIQHCFMPFOYEGW-UHFFFAOYSA-N
M.W : 375.27 Pubchem ID :66820441
Synonyms :

Calculated chemistry of [ 1256784-52-7 ]

Physicochemical Properties

Num. heavy atoms : 27
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.65
Num. rotatable bonds : 4
Num. H-bond acceptors : 5.0
Num. H-bond donors : 0.0
Molar Refractivity : 109.63
TPSA : 57.23 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -6.22 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 3.34
Log Po/w (WLOGP) : 2.58
Log Po/w (MLOGP) : 1.75
Log Po/w (SILICOS-IT) : 2.13
Consensus Log Po/w : 1.96

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 0.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.17
Solubility : 0.0253 mg/ml ; 0.0000674 mol/l
Class : Moderately soluble
Log S (Ali) : -4.22
Solubility : 0.0227 mg/ml ; 0.0000604 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -4.75
Solubility : 0.00675 mg/ml ; 0.000018 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 3.85

Safety of [ 1256784-52-7 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1256784-52-7 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 1256784-52-7 ]
  • Downstream synthetic route of [ 1256784-52-7 ]

[ 1256784-52-7 ] Synthesis Path-Upstream   1~1

  • 1
  • [ 740842-73-3 ]
  • [ 73183-34-3 ]
  • [ 1256784-52-7 ]
YieldReaction ConditionsOperation in experiment
100% With potassium acetate In dimethyl sulfoxide at 80℃; for 1.5 h; 1,1-Dimethylethyl 7-bromo-2,3-dihydro-l,4-benzoxazepine-4(5H)- carboxylate (reagent preparation 21) (5.0 g, 20.1 mmol), bis(pinacolato)diboron (5.6 g, 22.1 mmol), potassium acetate (5.9 g, 60.2 mmol) and [1,1 '- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (440 mg, 0.62 mmol) were heated in DMSO (5 mL) solution at 80 0C for 1.5 h. The mixture was then cooled to room temperature and diluted with an excess of ethyl acetate and filtered through a bed of celite. The filtrate was partitioned with IM aqueous hydrochloric acid and the organic phase washed with brine and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated and the residue purified by silica chromatography using 4: 1 hexanes:ethyl acetate as eluent to give tert-butyl 7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2-yl)-2,3-dihydrobenzoxazepine-4(5)-carboxylate (7.6g, 100percent). 1H NMR (400 MHz, CDCl3): 7.77 (s, 0.4H), 7.67 (s, IH), 7.65 (s, 0.6H), 7.04- 6.98 (m, IH), 4.54 (s, 0.7H), 4.43 (s, 1.3H), 4.09-4.01 (m, 2H), 3.79 (dd, 2H), 1.40 (br s, 9H), 1.26 (s, 12H). MS (EI) for C20H30BNO5: 376 (MH+).
100% With potassium acetate In dimethyl sulfoxide at 80℃; for 1.5 h; STEP 1 : 1,1 -Dimethylethyl 7-bromo-2,3-dihydro- 1 ,4-benzoxazepine-4(5H)- carboxylate (reagent preparation 13) (5.0 g, 20.1 mmol), bis(pinacolato)diboron (5.6 g, 22.1 mmol), potassium acetate (5.9 g, 60.2 mmol) and [1,1'- bis(diphenylphosphino)ferrocene]dichloropalladium(II) (440 mg, 0.62 mmol) were heated in DMSO (5 mL) solution at 8O0C for 1.5 h. The mixture was then cooled to room temperature and diluted with an excess of ethyl acetate and filtered through a bed of celite. The filtrate was partitioned with IM aqueous hydrochloric acid and the organic phase washed with brine and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated and the residue purified by silica chromatography using 4:1 hexanes:ethyl acetate as eluent to give tert-butyl 7-(4,4,5,5-tetramethyl-l,3,2- dioxaborolan-2-yl)-2,3-dihydrobenzoxazepine-4(5H)-carboxylate (7.6g, 100percent). 1H NMR (400 MHz, CDCl3): 7.77 (s, 0.4H), 7.67 (s, IH), 7.65 (s, 0.6H), 7.04-6.98 (m, IH), 4.54 (s, 0.7H), 4.43 (s, 1.3H), 4.09-4.01 (m, 2H), 3.79 (dd, 2H), 1.40 (br s, 9H), 1.26 (s, 12H). MS (EI) for C20H30BNO5: 376 (MH+).
100% With potassium acetate In dimethyl sulfoxide at 80℃; for 1.5 h; 1,1 -Dimethylethyl 7-bromo-2,3-dihydro- 1 ,4-benzoxazepine-4(5Η)- carboxylate (5.0 g, 20.1 mmol), bis(pinacolato)diboron (5.6 g, 22.1 mmol), potassium acetate (5.9 g, 60.2 mmol) and [l,r-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (440 mg, 0.62 mmol) were heated in DMSO (5 mL) solution at 80 0C for 1.5 h. The mixture was then cooled to room temperature and diluted with an excess of ethyl acetate and filtered through a bed of celite. The filtrate was partitioned with IM aqueous hydrochloric acid and the organic phase washed with brine and dried over anhydrous sodium sulfate. The mixture was filtered and concentrated and the residue purified by silica chromatography using 4:1 hexanes:ethyl acetate as eluent to give tert-butyl 7-(4,4,5,5-tetramethyl-l,3,2-dioxaborolan-2- yl)-2,3-dihydrobenzoxazepine-4(5)-carboxylate (7.6g, 100percent). 1H NMR (400 MHz, CDCl3): 7.77 (s, 0.4H), 7.67 (s, IH), 7.65 (s, 0.6H), 7.04-6.98 (m, IH), 4.54 (s, 0.7H), 4.43 (s, 1.3H), 4.09-4.01 (m, 2H), 3.79 (dd, 2H), 1.40 (br s, 9H), 1.26 (s, 12H). MS (EI) for C20H30BNO5: 376 (MH+).
78% With (1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride; potassium acetate In 1,4-dioxane at 90℃; for 3 h; Inert atmosphere To a solution of tert-butyl 7-bromo-2,3-dihydrobenzo[f][1,4]oxazepine-4(5H)carboxylate(800 mg,2.44 mmol)in 1,4-dioxane (5 mL)was added 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane)(1.24 g,4.88 mmol),KOAc (718 mg,7.31 mmol)and [1,1'bis(diphenylphosphino)ferrocene]dichloropalladium(II)(178 mg,0.24 mmol). The mixture was15 heated to 90 oc for 3 h under a nitrogen atmosphere. After cooling to room temperature,EtOAc(60 mL)was added and washed with water (50 mL x 2). The organic layer was dried over anhydrous Na2S04,filtered and concentrated in vacuo. The crude residue was purified by silicagel column chromatography (petroleum ether/EtOAc = 3: 1)to give the title compound (71 0 mg,78percent)as a white solid. LCMS M/Z (M+Na)398.

Reference: [1] Patent: WO2010/138490, 2010, A1, . Location in patent: Page/Page column 60
[2] Patent: WO2010/135568, 2010, A1, . Location in patent: Page/Page column 52-53
[3] Patent: WO2010/138487, 2010, A1, . Location in patent: Page/Page column 158-159
[4] Patent: WO2017/205536, 2017, A2, . Location in patent: Page/Page column 130; 131
Same Skeleton Products
Historical Records

Related Functional Groups of
[ 1256784-52-7 ]

Organoboron

Chemical Structure| 1310404-00-2

[ 1310404-00-2 ]

tert-Butyl 4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)piperazine-1-carboxylate

Similarity: 0.88

Chemical Structure| 889865-34-3

[ 889865-34-3 ]

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-carboxylate

Similarity: 0.88

Chemical Structure| 905273-91-8

[ 905273-91-8 ]

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindoline-2-carboxylate

Similarity: 0.84

Chemical Structure| 2126812-29-9

[ 2126812-29-9 ]

Benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethylcarbamate

Similarity: 0.82

Chemical Structure| 330794-35-9

[ 330794-35-9 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate

Similarity: 0.81

Amides

Chemical Structure| 1310404-00-2

[ 1310404-00-2 ]

tert-Butyl 4-(2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)ethyl)piperazine-1-carboxylate

Similarity: 0.88

Chemical Structure| 889865-34-3

[ 889865-34-3 ]

tert-Butyl 4-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenoxy)piperidine-1-carboxylate

Similarity: 0.88

Chemical Structure| 905273-91-8

[ 905273-91-8 ]

tert-Butyl 5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)isoindoline-2-carboxylate

Similarity: 0.84

Chemical Structure| 2126812-29-9

[ 2126812-29-9 ]

Benzyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethylcarbamate

Similarity: 0.82

Chemical Structure| 330794-35-9

[ 330794-35-9 ]

tert-Butyl 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzylcarbamate

Similarity: 0.81

Related Parent Nucleus of
[ 1256784-52-7 ]

Other Aromatic Heterocycles

Chemical Structure| 1161362-35-1

[ 1161362-35-1 ]

tert-Butyl 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazine-4(3H)-carboxylate

Similarity: 0.81

Chemical Structure| 1002727-88-9

[ 1002727-88-9 ]

2-(Chroman-6-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane

Similarity: 0.67

Chemical Structure| 1361110-64-6

[ 1361110-64-6 ]

7-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydro-2H-benzo[b][1,4]oxazine

Similarity: 0.66

Chemical Structure| 943994-02-3

[ 943994-02-3 ]

6-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)-2H-benzo[b][1,4]oxazin-3(4H)-one

Similarity: 0.66

Chemical Structure| 952681-82-2

[ 952681-82-2 ]

2-(1'-(tert-Butoxycarbonyl)spiro[chroman-2,4'-piperidine]-4-yl)acetic acid

Similarity: 0.58